Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Conditions:   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Gonadotroph Adenoma;   Pituitary Basophilic Adenoma;   Pituitary Chromophobe Adenoma;   Pituitary Eosinophilic Adenoma;   Prolactin Secreting Adenoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials